基于炎症解决的动脉样硬化治疗使用生物模拟纳米载体,载有专门的亲解决脂质介质
Maria Anghelache1, Geanina Voicu1, Ruxandra Anton1
1"Medical and Pharmaceutical Bionanotechnologies" Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, 050568, Bucharest, Romania.
Materials today. Bio
|April 21, 2025
概括
生物模拟性脂质纳米乳液中含有专门的亲溶解介质 (SPMs),可以有效地解决动脉样硬化病变的炎症. 这种新型的输送系统增强了动脉样硬化和其他炎症性疾病的治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
背景情况:
- 动脉样硬化 (ATH) 病变中的慢性炎症源于未解决的炎症反应.
- 专门的亲解决媒介 (SPMs) 对于解决炎症至关重要.
- 开发有效的SPM传递系统是提高其在动脉样硬化的治疗潜力的关键.
研究的目的:
- 评估被覆盖着巨细胞膜 (Bio-LN/SPMs) 的仿生脂质纳米乳液中结合的SPM的治疗潜力.
- 为了提高SPM稳定性,向性和生物活性,以解决动脉样硬化斑块炎症.
- 为了比较Bio-LN/SPM与自由SPM和标准纳米乳液的疗效.
主要方法:
- 使用了动脉样硬化的体外和体内实验模型.
- 在TNF-α激活的内皮/平滑肌细胞和LPS激活的巨细胞上测试了Bio-LN/SPMs,以减少炎症标志物.
- 在高脂肪饮食中静脉注射Bio-LN/SPM给4周和8周的ApoE缺乏的小鼠.
主要成果:
- 生物-LN/SPMs在体外显著降低了炎症标志物 (VCAM-1,MCP-1,iNOS,NLRP3),与自由的SPMs相比.
- 在体内,Bio-LN/SPM降低了血甘油三,改善了功能,减少了炎症蛋白 (C4d,C5b-9,IL-6,MCP-1).
- 在动脉样硬化小鼠中,Bio-LN/SPMs调节了单细胞亚群,促进了M2巨细胞的过渡,并降低了动脉样硬化小鼠的促炎细胞因子和脂质沉积.
结论:
- 与免费的SPM和标准纳米乳液相比,Bio-LN/SPM在解决与动脉样硬化相关的炎症方面表现出卓越的治疗效果.
- 生物模拟性巨细胞膜涂层增强了SPM传递和生物活性.
- 生物-LN/SPMs代表了对动脉样硬化和其他炎症状况的有希望的新疗法策略.
相关概念视频
Inflammation
51.0K
Overview
51.0K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
Inflammatory Response
1.6K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
99
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
99
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97


